Home » Stocks » SIOX

Sio Gene Therapies, Inc. (SIOX)

Stock Price: $2.73 USD -0.08 (-2.85%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $2.72 -0.01 (-0.37%) Jan 26, 7:30 PM
Market Cap 134.26M
Revenue (ttm) n/a
Net Income (ttm) -49.27M
Shares Out 46.73M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.73
Previous Close $2.81
Change ($) -0.08
Change (%) -2.85%
Day's Open 2.81
Day's Range 2.71 - 2.87
Day's Volume 879,964
52-Week Range 1.44 - 5.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

-  Generally well-tolerated with a favorable safety profile in five patients -  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6, ...

Zacks Investment Research - 1 month ago

Axovant (SIOX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 month ago

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically ...

Other stocks mentioned: AXGT
GlobeNewsWire - 2 months ago

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...

Other stocks mentioned: AXGT
GlobeNewsWire - 2 months ago

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...

Other stocks mentioned: AXGT
GlobeNewsWire - 2 months ago

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative disease...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Dr...

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtu...

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...

Other stocks mentioned: AXGT
Zacks Investment Research - 3 months ago

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020 Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020

Other stocks mentioned: AXGT
Zacks Investment Research - 3 months ago

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline ...

Other stocks mentioned: AXGT
GlobeNewsWire - 3 months ago

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will pre...

Other stocks mentioned: AXGT
The Motley Fool - 3 months ago

These underappreciated biotechnology start-ups could turn heads one day -- but not yet.

Other stocks mentioned: AXGT, BBIO
Seeking Alpha - 3 months ago

AXGT has promising gene therapy results in Parkinson's Disease.

Other stocks mentioned: AXGT
Zacks Investment Research - 4 months ago

Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Other stocks mentioned: AXGT
Seeking Alpha - 4 months ago

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXGT, AXP, JPM, KO, MCD, MRK, NKE, PFE, STRO, WMT
GlobeNewsWire - 4 months ago

NEW YORK and BASEL, Switzerland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...

GlobeNewsWire - 4 months ago

      - Parkinson's Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists

Other stocks mentioned: AXGT
GlobeNewsWire - 5 months ago

NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for ne...

Other stocks mentioned: AXGT
GlobeNewsWire - 5 months ago

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD           

GlobeNewsWire - 5 months ago

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...

Zacks Investment Research - 7 months ago

Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 7 months ago

NEW YORK and BASEL, Switzerland, June 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...

GlobeNewsWire - 7 months ago

-  Six-month data from low-dose cohort expected in Q4 2020 -  IND amended to include Type I (infantile onset) patients and to evaluate a higher dose -  Expect to initiate high-dose cohort ...

Zacks Investment Research - 7 months ago

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 5th

Other stocks mentioned: AXGT, GFI, PS, ZYXI
GlobeNewsWire - 9 months ago

Company’s balance sheet is now free of debt Company’s balance sheet is now free of debt

GlobeNewsWire - 9 months ago

NEW YORK and BASEL, Switzerland, April 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, toda...

Zacks Investment Research - 9 months ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 9 months ago

NEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...

GlobeNewsWire - 11 months ago

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten...

GlobeNewsWire - 11 months ago

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 1...

GlobeNewsWire - 11 months ago

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offerin...

GlobeNewsWire - 11 months ago

NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided f...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...

Zacks Investment Research - 1 year ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which ...

Zacks Investment Research - 1 year ago

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced ...

Zacks Investment Research - 1 year ago

Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...

Zacks Investment Research - 1 year ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 1 year ago

In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.

GlobeNewsWire - 1 year ago

BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag M...

Zacks Investment Research - 1 year ago

Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.

Benzinga - 1 year ago

Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird.

Zacks Investment Research - 1 year ago

On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological dis...

About SIOX

Sio Gene Therapies, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Ther... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Pavan Cheruvu
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
SIOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SIOX stock is "Buy." The 12-month stock price forecast is 8.88, which is an increase of 225.27% from the latest price.

Price Target
$8.88
(225.27% upside)
Analyst Consensus: Buy